Directory · MT
Biotechnology Research in Malta
A register of firms and the professionals working at them in the Biotechnology Research sector based in Malta. Browse the public index, then filter or export on Kipplo.
Companies
8 on file
Omniscope
Building the world's largest immune databank to inform therapy and develop diagnostics through a convergence of high-resolution immune cell sequencing and artificial intelligence. We bring together bright minds from multiple disciplines. We are driven to shorten the timeline from research to real-world human impact. Our motivation is to put science in service of humanity. Join us in our mission: Healthcare for everyone, everywhere. Science is we all.
11 to 50 staff
Neurotech International Ltd
Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated safety and efficacy results at 28 days, 20 weeks and 32 weeks of daily treatment with NTI164. The Company commenced a Phase randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. The Company will also be conducting additional Phase I/II trial in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with a Phase I/II trial in Cerebral Palsy during CY2023. Additionally, Neurotech is commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech please visit
11 to 50 staff
Tarsos
Our wearable in-shoe system allows for continuous foot health monitoring in patients living with diabetes.
1 to 10 staff
The Bioarte
The BioArte is an innovative player in the field of biomolecular research, highly specialized in researching the human microbiota and microbial communities in other environments. The aim of our diagnostic analyses is towards all types of microorganisms, ranging from those which are essential for our well-being to those which are pathogenic. The BioArte is developing personalised remedies for several diseases by providing molecules obtained from human and animal microbiota. Located in the heart of Malta, Europe — between two dynamic establishments just 15 minutes of each other — The founders of the BioArte Ltd have been caring for patients and customers from around the world for more than 25 years. Our scientific founders have pioneered our modern understanding of how the immune system senses microbes and contributed seminal discoveries to the microbiome field, including the identification of immune-regulating and immune-potentiating bacteria that live in association with humans, animals, and flora.
11 to 50 staff
Comed Therapeutics
COMED Therapeutics is a biotechnology company developing potentially first-in-class intracellular therapies. Founded in 2019, now headquartered at the Malta Life Sciences Park, COMED is advancing novel technologies that deliver antibodies, proteins, peptides, and RNA directly into cells—unlocking disease targets long considered “undruggable.” Our patented platform enables the delivery of therapeutic molecules into the cellular interior. Combined with our portfolio of patented engineered antibodies, this dual approach creates new opportunities to overcome the limitations of conventional biologics and treat diseases driven by intracellular mechanisms. Three therapeutic candidates are advancing through preclinical research. The lead program in pancreatic cancer, the deadliest of all major cancers, directly targets oncogenic drivers inside tumor cells. Additional programs are focused on spinal muscular atrophy (SMA), a devastating neuromuscular disorder, and malaria, one of the world’s most persistent health burdens. Validation studies have demonstrated our platform’s ability to enter cancer cells and block mutant signaling proteins responsible for tumor growth—a milestone with strong first-in-class potential. This positions COMED for accelerated development pathways, including Breakthrough Therapy and Orphan Drug opportunities. Our progress is supported by competitive funding and national recognition, including two separate research grants from Xjenza Malta—one for malaria and another for cancer—as well as innovation financing from Malta Enterprise. Operating from a state-of-the-art laboratory and supported by strategic European partnerships, COMED’s team of exceptional scientists—with expertise in molecular biology, genetics, pharmacokinetics, and other medical fields—is united by a clear purpose: redefining the concept of precision medicine by reaching inside the cell, developing therapies designed to strike with accuracy and leave everything else untouched.
11 to 50 staff
Omnigene Medical Technologies Ltd
Omnigene medical technologies is actively engaged in innovations promoting accurate and precise test results from low volume and difficult samples in the area of cancer testing, and neurological conditions. The tests can be used in the clinic for patient surveillance, and in research laboratories to measure multiple analytes in a low volume or highly degraded material. The methodologies are versatile and can be used in various health areas, in research models, in archival material to minimise time lapse for validation of biomarkers, in liquid biopsies (circulating tumour cells and exosomes) and in clinical trials. The company offers genetic services in the clinical sector and microbiome analysis in health and wellbeing. The company also invests in development projects aimed to enhance existing technologies and to merge technologies towards specific aims. As a contract research organisation (CRO) we leverage our optimised methodologies to support the academic community and biotech companies to measure multiple analytes (DNA, RNA and proteins) in low input and low quality material. Omnigene Medical Technologies Ltd also represents companies that offer high-end technologies for the academic research laboratories and promotes cutting edge technologies for early detection of disease and its progression.
1 to 10 staff
De Novo Cell
De Novo Cell™ is a spinout from the University of Malta registered in Europe. The company is researching a proprietary procedure for the rapid and efficient production of induced pluripotent stem cells (iPSCs) from cord blood mononuclear cells and peripheral blood cells. Conversion rates between 80-90% are obtained in less than a month. The method uses small-molecule inducers and does not require feeder layer support, and the iPSCs produced are free of any genetic modification. De Novo Cell aims to carry out research and advance stem cell technology, with the aim of producing stem cells which are easily available in hospitals to treat multiple diseases.
1 to 10 staff
Sib Laboratories
SIB Laboratories is a limited company located in Malta. Its main goals are identification, evaluation and valorisation of research projects with high economical and scientific potential, research and management of partnership between potential suppliers & customers for economical, technical or scientific valorisation of these projects. SIB Lab. Is a “added value partner” offering: A Multidisciplinary team Implicated in innovative research centres With exclusive entries in specific and restricted research centres Scientific screening, selection and validation of collaborative projects proposals SIB Lab wants to be the “added value link” between Research, Development and Application teams by acting: As a facilitating Agent for partnership; Management of contacts & relationship between collaborative teams; To solve administrative, technical, scientific and legal problems between partners; To submit new scientific projects to parties.
1 to 10 staff
